Save
esh.org
Functional imaging characteristics of myeloma - promising now, predicting in the future?
ESH eLearning, Elena ZAMAGNI, 261690
What is old - from biology of the disease to patient
ESH eLearning, Sonja ZWEEGMAN, 261691
High risk disease - from definition to treatment
ESH eLearning, Jonathan KEATS, 261675
Double hit also in myeloma? The role of genome sequencing
ESH eLearning, Gareth MORGAN, 261682
New Insights into the early-stage bone colonization of disseminated cancer cells
ESH eLearning, Xiang H.F. Zhang, 261707
Molecular regulation and heterogeneity in quiescence exit of human haematopoietic stem cells
ESH eLearning, Elisa Laurenti, 261706
Subversion of systemic glucose metabolism as a mechanism to support the growth of leukaemia cells
ESH eLearning, Haobin Ye, 261705
Fatty acid metabolism and bone marrow adipocytes in AML
ESH eLearning, Yoko Tabe, 261704
The HSC niche in aging
ESH eLearning, Hartmut Geiger, 263172
Genomic landscape of Waldenström’s macroglobulinemia
ESH eLearning, Steven Treon, 233978
POEMS syndromes
ESH eLearning, Arnaud Jaccard, 233979
How to judge the value of a clinical trial: HR, median PFS, p-value
ESH eLearning, Robert Hills, 233980
Real-world evidence –What is it and what can it tell us?
ESH eLearning, Kwee Yong, 233981
Optimal cost/safety/efficacy/QOL ration
ESH eLearning, Jean-Luc Harousseau, 233982
New generation sequencing in multiple myeloma
ESH eLearning, Nikhil Munshi, 233973
When and how to treat first relapse according to the guidelines
ESH eLearning, Meletios A Dimopoulos, 233974
New drugs, new immune therapies, new targeted therapies
ESH eLearning, Enrique Ocio, 233975
Adoptive cell therapy in multiple myeloma
ESH eLearning, Jesus Berdeja, 233976
Future combinations for the treatment of MM
ESH eLearning, Kenneth C. Anderson, 233977
From MGUS to MM: Do all clones take the same road?
ESH eLearning, Madhav Dhodapkar, 233965
Leukemic stem cells modulate the bone marrow microenvironment
ESH eLearning, María-Victoria Mateos, 233966
Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)
ESH eLearning, Hervé Avet-Loiseau, 233967
Primary plasma cell leukaemia and extramedullary disease
ESH eLearning, Niels VAN DE DONK, 233968
Geriatric assessment: is it required?
ESH eLearning, Alessandra Larocca, 233969
European guidelines
ESH eLearning, Sonja ZWEEGMAN, 233970
Ongoing trials for newly diagnosed patients not eligible for stem cell transplantation, and frontline treatment when new drugs are not available
ESH eLearning, Kwee Yong, 233971
Induction therapy: triplet, quadruplet?
ESH eLearning, Philippe Moreau, 233972
Geriatric assessment in multiple myeloma: is it required?
ESH eLearning, Alessandra Larocca, 234000
MRD as a response assessment in elderly multiple myeloma
ESH eLearning, Alessandra Larocca, 234001
Vaccines to prevent progression or relapse in multiple myeloma
ESH eLearning, Ann van de Velde, 234002
How do we define a ‘cure’ in myeloma?
ESH eLearning, Annemiek Broijl, 234003
Treatment options for high-risk myeloma
ESH eLearning, Annemiek Broijl, 234004
Smoldering myeloma treatment landscape & MRD negativity
ESH eLearning, Annemiek Broijl, 234005
Dendritic cell vaccine for MM: trial updates with maintenance & checkpoint inhibitor pidilizumab
ESH eLearning, David Avigan, 234006
Investigating vaccines for hem-onc: key questions
ESH eLearning, David Avigan, 234007
What is the role of PET/CT in myeloma management?
ESH eLearning, Elena ZAMAGNI, 234008
Where will we be in MM management 5 years from now?
ESH eLearning, Elena ZAMAGNI, 234009
A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor
ESH eLearning, Enrique Ocio, 234010
Immunotherapeutics against multiple myeloma: it's all about BCMA
ESH eLearning, Enrique Ocio, 234011
Are BCL2 and MCL1 inhibitors the key against myeloma?
ESH eLearning, Enrique Ocio, 234012
The evolving imaging of multiple myeloma
ESH eLearning, Evangelos Terpos, 234013
Real world data: bortezomib-based therapy for R/R myeloma
ESH eLearning, Evangelos Terpos, 234014
Real world data for len/dex in second-line myeloma: what does this tell us?
ESH eLearning, Evangelos Terpos, 234015
Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM
ESH eLearning, Evangelos Terpos, 234016
Treatment sequencing in multiple myeloma: a multitude of options
ESH eLearning, Heinz Ludwig, 234017
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
ESH eLearning, Heinz Ludwig, 234018
Smoldering multiple myeloma: what is the current definition & new screening programme
ESH eLearning, Irene GHOBRIAL, 234019
Opinion: MRD sequencing test approval in multiple myeloma
ESH eLearning, Irene GHOBRIAL, 234020
CAR T-cells for multiple myeloma: update & what's in store for ASH 2018
ESH eLearning, Jesus Berdeja, 234021
Toxicity profile for CAR T-cells in multiple myeloma
ESH eLearning, Jesus Berdeja, 234022
MRD and disease eradication in myeloma
ESH eLearning, Jesús San Miguel, 234023
Early detection and intervention in myeloma: a critical point
ESH eLearning, Jesús San Miguel, 234024
Continuous vs. fixed duration therapy for multiple myeloma?
ESH eLearning, Jesús San Miguel, 234025
Future treatment combinations for myeloma
ESH eLearning, Kenneth Anderson, 234026
MRD detection in myeloma: approval of NGS assay & questions for the clinic
ESH eLearning, Kenneth Anderson, 234027
Frontline transplant-ineligible MM treatment
ESH eLearning, Kwee Yong, 234028
Combining bortezomib and lenalidomide-based regimens for frontline MM
ESH eLearning, Kwee Yong, 234029
Real world evidence: what is it and what can it tell us?
ESH eLearning, Kwee Yong, 234030
How should smoldering multiple myeloma be monitored?
ESH eLearning, María-Victoria Mateos, 234031
Update on recent smoldering multiple myeloma trials
ESH eLearning, María-Victoria Mateos, 234032
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
ESH eLearning, María-Victoria Mateos, 234033
Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
ESH eLearning, María-Victoria Mateos, 234034
Plasma cell leukemia and extramedullary disease in multiple myeloma
ESH eLearning, Niels van de Donk, 234035
Daratumumab in myeloma update: expanding indications
ESH eLearning, Niels van de Donk, 234036
A novel mechanism of action for daratumumab in myeloma
ESH eLearning, Niels van de Donk, 234037
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
ESH eLearning, Niels van de Donk, 234038
MRD negativity using deep sequencing is a major prognostic factor in myeloma
ESH eLearning, Nikhil Munshi, 234039
MRD sequencing test approved for MM in the US
ESH eLearning, Nikhil Munshi, 234040
Genomics shed light on targeted treatment for myeloma
ESH eLearning, Nikhil Munshi, 234041
Frontline treatment of transplant-ineligible MM: a changing landscape
ESH eLearning, Noopur Raje, 234042
Quadruplet regimens and antibodies for newly diagnosed multiple myeloma
ESH eLearning, Noopur Raje, 234043
CAR T-cells for myeloma: an update
ESH eLearning, Noopur Raje, 234044
PVX-410 vaccine for smoldering myeloma
ESH eLearning, Noopur Raje, 234045
Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
ESH eLearning, Noopur Raje, 234046
Judging the value of a clinical trial in hem-onc
ESH eLearning, Robert Hills, 234047
Opinion: value of MRD as an endpoint in hem-onc clinical trials
ESH eLearning, Robert Hills, 234048
UK NCRI AML17 trial update: everolimus addition for consolidation
ESH eLearning, Robert Hills, 234049
Monoclonal antibodies: current and future potential
ESH eLearning, Saad Usmani, 234050
Targeting BCMA with bispecific antibodies in R/R myeloma
ESH eLearning, Saad Usmani, 234051
Updated POLLUX results for early relapsed myeloma patients
ESH eLearning, Saad Usmani, 234052
Whole genome sequencing opens door for targeted Waldenström’s therapy
ESH eLearning, Steven Treon, 234053
Exploring treatment options against different Waldenström’s mutations
ESH eLearning, Steven Treon, 234054
Mapping the genomic landscape of Waldenström’s Macroglobulinemia
ESH eLearning, Steven Treon, 234055
How to predict response in silico and in vitro?
ESH eLearning, David Weinstock, 234062
Design of innovative clinical trials: still a role for phase III trials?
ESH eLearning, Andrew Davies, 234063
Minimal biological measurement requirements for DLBCL: What do clinicians need to have measured?
ESH eLearning, Lisa RIMSZA, 234061
Rational Targeting of the NuRD Complex For Fetal Hemoglobin Induction 2019 ESH Erythropoiesis
ESH eLearning, Daniel Bauer, 265280
Fanconi anaemia
ESH eLearning, Carlo Dufour, 265281
Autoimmune haemolytic anaemias
ESH eLearning, Wilma Barcellini, 265282
Inflammation as a determinant of ineffective erythropoiesis in myelodysplastic syndromes
ESH eLearning, Alan List, 265283
TGF-b pathway inhibitors in low risk MDS
ESH eLearning, Valeria Santini, 265284
New approches to managing sickle cell disease
ESH eLearning, David Rees, 265285
Heme regulation and GATA1
ESH eLearning, Janis Abkowitz, 265286
Gene editing for thalassemia and sickle cell disease
ESH eLearning, Daniel Bauer, 265287
Gene therapy for thalassaemia / sickle cell disease
ESH eLearning, Alexis A. Thompson, 265288
Diamond-Blackfan anaemia : genetic and clinical complexity exemplified by 3 cases encountered in clinical practice
ESH eLearning, Marcin Wlodarski, 265289
Which pro-survival BCL-2 family member should be targeted for the treatment of which type of leukaemia or lymphoma
ESH eLearning, Andreas STRASSER, 234057
Targeting MALT1 signaling: preclinical data and perspectives in the clinic
ESH eLearning, Daniel KRAPMANN, 234058
The genetic landscape of MCL – more than CyclinD1?
ESH eLearning, Eias CAMPO, 234059
T-NHL: novel targets and therapies - How can we move forward?
ESH eLearning, Norbert SCHMITZ, 234060

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings